// App-Quantinova.ai

9088 : Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.

Researchers

Presenter

  • Vassiliki Papadimitrakopoulou

Principal Investigators

  • David R. Gandara

  • Fred R. Hirsch

  • Philip C. Mack

  • Hossein Borghaei

  • Corey J. Langer

  • Jeffrey A. Engelman

  • Martin J. Edelman

  • Kathy S. Albain

  • Primo Lara

  • Charu Aggarwal

  • Mark A. Socinski

  • Scott N. Gettinger

  • Lyudmila Bazhenova

  • Shakun M. Malik

  • Vincent A. Miller

  • Ellen V. Sigal

  • Karen Kelly

  • Roy S. Herbst

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • University of California, San Francisco, CA

  • Univ of Colorado Cancer Ctr, Denver, CO

  • UC Davis Comprehensive Cancer Center, Sacramento, CA

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • University of Maryland School of Medicine, Baltimore, MD

  • Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, IL

  • University of Pennsylvania, Philadelphia, PA

  • University of Pittsburgh, Pittsburgh, PA

  • Yale Comprehensive Cancer Center, New Haven, CT

  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, San Diego, CA

  • National Cancer Institute, Rockville, MD

  • Foundation Medicine, Inc, Cambridge, MA

  • Friends of Cancer Research, Washington, DC

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

Locations

  • United States

Companies

  • Foundation Medicine,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Fibroblast growth factor receptor

  • Hepatocyte growth factor

Drug/Treatment

  • Palbociclib

  • Ipilimumab

  • Erlotinib hydrochloride

  • Nivolumab

  • Taselisib

  • Durvalumab

  • AZD-4547

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02154490

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved